A new study in mouse cortical neurons suggests that fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator currently used to treat MS, may reduce beta-amyloid neurotoxicity (Doi et al. PLoS One 2013;8:e6; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC3625222/pdf/pone.0061988.pdf).
Latest News
MS treatment failure: who is at risk?
March 19, 2014A new study in Brazil reports that risk factors for treatment failure among MS patients are comparable to those reported for patients in the northern hemisphere (Damasceno et al. J Neurol Sci 2013;324:29-33). Read More
Neurodegenerative disease and high-voltage power lines
March 5, 2014Over the past few decades there have been numerous studies investigating whether proximity to high-voltage power lines and exposure to electromagnetic fields (EMF) contributes to the development of neurodegenerative diseases. The most recent epidemiological study reports that living near a power line does not increase the risk of developing dementia, Parkinson’s disease or motor neuron disease (Frei et al. Am J Epidemiol 2013; epublished April 9, 2013). Read More
Epstein-Barr and MS: meta-analysis
March 5, 2014A new meta-analysis of 39 studies (n=10,864) has concluded that there is an association between Epstein-Barr virus (EBV) seropositivity and MS (Almohmeed et al. PLoS One 2013;8:e61110; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC3621759/pdf/pone.0061110.pdf). Seroprevalence was determined for three anti-EBV antibodies: anti-EBV nuclear antigen 1 (anti-EBNA-1) or EBNA complex; antiviral capsid antigen (anti-VCA); and anti-Early Antigen (anti-EA). Read More